Abstract Search

ea0063gp59 | Acromegaly and GH | ECE2019

Effects of pegvisomant and pasireotide LAR on incidence of vertebral fractures in patients with acromegaly resistant to treatment with first-line somatostatin analogs

Chiloiro Sabrina , Giampietro Antonella , Bianchi Antonio , Bima Chiara , Frara Stefano , Mirra Federica , Donfrancesco Federico , Fleseriu Cara Maria , Fleseriu Maria , Giustina Andrea , Laura De Marinis , Pontecorvi Alfredo

Purpose: Osteopathy is an emerging complication of acromegaly characterized by increased bone turnover, deterioration in bone microarchitecture and high risk of vertebral fractures (VFs). In somatostatin analog (SSA)-resistant patients (pts), Pegvisomant (PegV) and Pasireotide LAR (Pasi) are used for acromegaly treatment, but their effect on skeletal health is still not defined.Methods: In a longitudinal international multicenter study, we evaluated inci...

0 shares

Endocrine Abstracts

Effects of pegvisomant and pasireotide LAR on incidence of vertebral fractures in patients with acromegaly resistant to treatment with first-line somatostatin analogs

BiosciAbstracts